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Global prevalence increase of diabetes type 2 and gestational diabetes (GDM) has led to increased awareness and screening of
pregnant women for GDM. Ideally screening for GDM should be done by an oral glucose tolerance test (oGTT), which is laborious
and time consuming. A randomized glucose test incorporated with anthropomorphic characteristics may be an appropriate
cost-effective combined clinical and biochemical screening protocol for clinical practice as well as cutting down on oGTTs. A
retrospective observational study was performed on a randomized sample of pregnant women who required anOGTT during their
pregnancy. Biochemical and anthropomorphic data along with obstetric outcomes were statistically analyzed. Backward stepwise
logistic regression and receiver operating characteristics curves were used to obtain a suitable predictor for GDM without an
oGTT and formulate a screening protocol. Significant GDM predictive variables were fasting blood glucose (𝑝 = 0.0001) and
random blood glucose (𝑝 = 0.012). Different RBG and FBG cutoff points with anthropomorphic characteristics were compared to
carbohydratemetabolic status to diagnoseGDMwithout oGTT, leading to a screening protocol. A screening protocol incorporating
IADPSGdiagnostic criteria, BMI, and different RBGandFBGcriteriawould help predictGDMamonghigh-risk populations earlier
and reduce the need for oGTT test.
1. Introduction
In Europe, type 2 diabetes mellitus (T2DM) and impaired
glucose tolerance (IGT) are on the increase, with 56 million
individuals reportedly suffering fromT2DMand 60.6million
having IGT [1, 2]. The apparent rising rates of T2DM/IGT
and obesity are expected to contribute to a concomitant rise
in GDM prevalence rates [3, 4]. The International Diabetes
Federation (IDF) reported that, in 2013, an estimate of 10.9%
of pregnancies in Europe suffered from gestational diabetes
mellitus (GDM) [2]. Having a high prepregnancy body mass
index (BMI) is a known risk factor for the development
of GDM [3]. The Mediterranean population is particularly
susceptible to both T2DM and obesity and hence has a
concomitant relatively high prevalence of GDM [5, 6]. Malta
is a small island in the middle of the Mediterranean Sea,
with high prevalence of obesity as well as type 2 diabetes
mellitus. The GDM prevalence rate in this population has
been estimated in 2010 to be 16.5% of the whole pregnant
population using the newly proposed International Associ-
ation of Diabetes and Pregnancy Study Group (IADPSG)
diagnostic criteria [4, 5]. The high prevalence of obesity and
diabetes mellitus in the Maltese population has been linked
to intrauterine nutritional environment adverse effects and to
genetic influences [6, 7].
Screening for gestational diabetes during pregnancy has
become a commonpractice amongobstetricians. Two screen-
ing options are possible, universal screening with an oral
glucose tolerance test (oGTT) or screening based on the
identification of clinical risk factors. Pregnant women should
ideally be screened for GDM with a routine oGTT between
24and 28 weeks of gestational age, since this is the time
wheremost hormonal changes occur and any possible insulin
resistance would be detected [8]. Due to lack of international
GDM screening strategy, a recent review on the different
screening practices across Europe found that there was lack
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of consistency in screening practices for GDM. In 2014, it
was stated that 70% of the 42 European countries routinely
offer universal screening for GDM to all pregnant women
while the remaining follow a targeted risk criteria approach
and screen only high-risk pregnant women [9]. The choice
of screening method in use by specific health providers
often depends on risk-benefit and cost-effectiveness ratios.
Diagnostic criteria also vary from one country to another,
though there is increasing acceptance, includingMalta, of the
IADPSG criterion [10].
In Malta, GDM screening is primarily currently based
on the identification of high-risk individuals based on their
anthropomorphic and clinical characteristics, supplemented
by a convenient venous blood glucose estimate. The aim of
this present study was to investigate the role of a convenient
untimed random venous blood glucose estimation in iden-
tifying the individuals at risk of GDM and thus propose a
cost-effective combined clinical and biochemical screening
protocol for clinical practice.
2. Materials and Methods
A retrospective observational study was done to evaluate the
screening of pregnant women who had undergone an oGTT
during their pregnancy and thus had a definite diagnosis of
their carbohydrate metabolic status. All the pregnant women
attending the first antenatal visit in the national hospital
were invited to participate in the study and undergo a 75-
gram oGTT at about 24–28 weeks of pregnancy.The national
hospital in Malta caters for over 95% of all maternities in the
Maltese Islands. The selection process may have contributed
to an element of bias since individuals with high-risk charac-
teristics including an elevated BMI were more likely to have
been encouraged by the attending clinicians to participate
than those with low risk characteristics.The study population
however included amix of high-risk and low risk individuals.
Pregnant women who had a known history of any form of
diabetes prior to becoming pregnant were excluded. A total
of 401 pregnant women underwent an early third trimester
75-gram oGTT over a period of twelve months between June
2011 and June 2012 atMater Dei General Hospital, Malta.This
population sample accounts for about 10% of the obstetric
population. Besides the blood glucose estimations including
random blood glucoses (RBG), fasting blood glucose (FBG),
and 1 hr and 2 hr oGTT, further biological data was collected
including maternal age and anthropomorphic characteristics
of the mother (including self-reported weight of the mother
before becoming pregnant and the measured height of the
mother). Venous blood for glucose estimation was collected
in a fluoride tube and stored in a fridge. The samples
were transported in a cooler to the hospital’s biochemistry
laboratory as soon as the oGTT test was completed or at
the end of the outpatient session [maximum period from
venesection to assay was four hours]. Fluoride tubes were
used in order to minimize glycolysis that would occur if
bloodwas placed in nonfluoride containing tubes.Once at the
laboratory, the fluoride tubes were centrifuged for 5 minutes
followed by glucose oxidation by a hexokinase photometric
analyzer. The rate of nicotinamide adenine dinucleotide
phosphate (NADP) formation during the reaction is directly
proportional to the glucose concentration and is measured
photometrically.
The population under study was divided into two groups
on the basis of the oGTT results: Group 1 included women
(𝑛 = 265) whose oGTT showed normal glycemic tolerance
(NGT) and Group 2 included women (𝑛 = 136) whose oGTT
confirmed GDM according to the IADPSG criteria. Ethical
approval was granted from the University of Malta Research
and Ethics Committee. Informed consent was obtained from
each mother prior to storage of any data.
The data was analyzed using SPSS version 21, using four
levels of analysis.
(1) The means and standard deviations for maternal age,
prepregnancy BMI, and the biochemical values (RBG
and FBG) for the two subgroups (NGT and GDM)
were compared statistically using Student’s 𝑡-test.
(2) The range of biochemical values (RBG, FBG, and 2nd
hour BG after OGTT) was statistically correlated to
the range of maternal age and of prepregnancy BMI
using Pearson’s correlation test.
(3) Backward stepwise logistic regression analysis was
performed on the population sample to establish
a significant predictor for GDM without using an
oGTT. The predictors under study were RBG, FBG,
maternal age, and prepregnancy BMI.
(4) Using a specific-designed excel spreadsheet pro-
gramme, the specificity, sensitivity, and positive and
negative predictor values for different RBG and FBG
cutoff points were worked out. Statistical significance
between NGT and GDM subgroups was assessed
using the chi square test.
3. Results
The GDM subgroup were shown to be statistically signifi-
cantly older than their NGT counterparts (mean maternal
age of 30.8 ± 5.33 range 17–44 years versus 29.2 ± 5.06
range 15–41 years: 𝑝 = 0.005). The mean prepregnancy
BMI (where available) in the GDM group (𝑛 = 112) was
higher than for the NGT group (𝑛 = 96) (28.3 + 7.0
versus 26.3 ± 6.4 kg/m2; 𝑝 = 0.03). The anthropomorphic
characteristic of prepregnancy BMI andmaternal age further
showed statistically significant correlation to the different
biochemical values (RBG, FBG, and 2 hr oGTT) (Table 1).
The GDM subgroup had significantly elevated mean
RBG values compared to their NGT counterparts (5.4 ±
1.5mmol/L versus 4.7 ± 0.9mmol/L: 𝑝 = 0.0001), as well
as elevated mean FBG values (5.0 ± 1.1mmol/L versus 4.3 ±
0.4mmol/L: 𝑝 = 0.0001). Both RBG (𝑝 = 0.012) and FBG
(𝑝 = 0.0001) were shown to have independent predictive
significance using a backward stepwise logistic regression
analysis. On the other hand, maternal age (𝑝 = 0.504) and
prepregnancy BMI (𝑝 = 0.772) showed no significance. ROC
curves were performed on the diagnosed GDM subgroup to
identify the best screening predictor. RBG was an inferior
predictor test when compared to FBG (sensitivity 69.2%;
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Table 1: The correlations between prepregnancy BMI and maternal
age to the different biochemical values.
RBG FBG 2 hr- oGTT
Prepregnancy BMI
(kg/m2)
𝑝 = 0.008 𝑝 = 0.001 𝑝 = 0.001
𝑅 = 0.140 𝑅 = 0.255 𝑅 = 0.253
𝑁 = 361 𝑁 = 360 𝑁 = 361
Maternal Age (Years)
𝑝 = 0.046 𝑝 = 0.003 𝑝 = 0.014
𝑅 = 0.105 𝑅 = 0.156 𝑅 = 0.129
𝑁 = 360 𝑁 = 359 𝑁 = 360
𝑃: statistical probability; 𝑅: Pearson’s coefficient;𝑁: number of observations.
specificity 43.3%; AUC 0.598; SE 0.36; 𝑝 = 0.005; 95% CI
0.527–0.668) with an indicative predictor GDM cutoff point
for FBG and RBG of 4.5mmol/L.
The sample data was divided according to the glucose
status (NGT and GDM) and to the RBG value obtained
during the booking visit. Table 2 illustrates the sensitivity,
specificity, and positive predictor and negative predictor
values for variable RBG cutoff values. A RBG cutoff point
of ≥6.0mmol/L was found to have a sensitivity of 26.3%
and a specificity of 90.1%. With this cutoff point, 15.4%
of the pregnant women would require a follow-up oGTT.
Using a lower cutoff point of ≥5.6mmol/L would increase the
sensitivity to 39.1%but decrease the specificity to 87.1%.About
21.7% of women would require follow-up with an oGTT.
TheROC curves analysis confirmed that FBGwas a better
screening toolwith prediction capabilities using a cutoff point
of 4.5mmol/L (sensitivity 60%; specificity 70%; AUC 0.703;
SE 0.035;𝑝 = 0.0001; 95%CI 0.634–0.771).Theuse of FBG for
screening at the higher cutoff point of ≥5.1mmol/L showed a
sensitivity of 48.1% and a specificity of 100.0%. None of the
women with a FBG ≥ 5.1mmol/L would require an oGTT
since this FBG level is considered diagnostic of GDM by the
IADPSG criteria. Bringing the screening FBGvalue down to a
cutoff point of≥4.5mmol/L increased the sensitivity to 60.2%
but decreased the specificity to 63.5%.This cutoff point value
would require 28.3% of the population to undergo an oGTT
(Table 3).
4. Discussion
The identification and management of women with GDM is
desirable to achieve improvement in neonatal and maternal
morbidities [11].The current study presents a populationwith
an apparent GDM prevalence of 33.9%. This is far in excess
of the previously reported prevalence rate of 16.5% in the
Maltese pregnant population [4, 5]. However, this study relied
on a convenient sample population and was not designed as
an epidemiological study. This led to potential bias selection
of high-risk individuals, thus accounting for the apparent
excessive higher prevalence rate in this study when compared
to previous epidemiologically based studies.
Biochemical screening with a conveniently timed RBG
test, as identified in other studies and systemic reviews, was
found to be statistically inferior when compared to a FBG test
as a predictive tool for GDM [12]. In fact the AUC value of
the RBG falls out of the confidence interval of theAUC for the
FBG. This study’s ideal predictive cutoff value for RBG was
of ≥4.5mmol/L, where women obtaining this value or above
can be considered at risk of GDM. While associated with a
sensitivity of 69.2%, this cutoff point however is associated
with a specificity of only 43.3% so that about 57% of the
pregnant population would be identified as being at risk
of GDM. An oGTT would therefore be required in 60.9%
of the population. When different RBG ranges were set up
and compared to carbohydrate metabolic status as diagnosed
by oGTT, the ideal cutoff RBG value was found to be
≥5.6mmol/L, identifying 39.1% of the GDM population.This
however would require an oGTT to be performed in 21.7% of
the population. A study by Jowett et al. showed similar results
where, at a threshold of 5.6mmol/L, the RBGhad a sensitivity
varying between 25% (95% CI 18–27%) and 47% (95% CI
37–56%) with corresponding specificity between 97% (95%
CI 91–99%) and 74% (95% CI 66–81%) [13]. An alternative
cutoff of ≥6.0mmol/L would identify 26.3% of the GDM
population but require an oGTT to be performed in only
15.4% of the pregnant population. A systemic review on the
accuracy of RBG as a screening test found that sensitivities
and specificities varied from a specificity of 100% and a
sensitivity of 20–30% to 100% sensitivity with a specificity
of 40%. This study concluded that performing just a RBG
measure is inadequate to screen for GDM [14]. The cutoff
choice should be therefore made on a cost-benefit criterion
by individual health providers, keeping cognizant of the costs
and inconvenience of the oGTT to the health provider and
the woman. It is important in the clinical setting that venous
blood glucose estimation in order to be successful, to be
delivered to the biochemistry laboratory as quick as possible.
The transit time is crucial even in the presence of fluoride,
since glucose decays quite rapidly at room temperature, so
that in an hour a fasting sample with a true of 5.4mmol/L
would probably be reported as less than 5mmol/L.
A FBG assessment used for screening would identify
48.1% of the GDM population using the IADPSG diagnostic
cutoff value of ≥5.1mmol/L [15]. A lower screening cutoff
FBG value of ≥4.5mmol/L would identify a greater pro-
portion (60.2%) of GDM women but would require about
28.3% of the pregnant population to undergo an oGTT.
Interestingly, in this study, the ideal cutoff points for both
the RBG and FBG were similar at ≥4.5mmol/L. This could
be that pregnant women while waiting for their booking visit
consultation may end up unintentionally fasted by the time
their blood sample is taken and checked.
A high self-reported prepregnancy BMI (>30 kg/m2) also
showed a definite statistical correlation to the different blood
glucose values, with a borderline nonstatistical significant
correlation to carbohydrate metabolic status. The lack of
statistical significance could be due to the fact that the
prepregnancy body weight was self-reported possibly with a
tendency to underrepresent actual body weight.Maternal age
in this study failed to show a useful correlation, though GDM
women tended to be older.
On the basis of this study, a management flowchart
for a cost-effective screening programme can be proposed
(Figure 1). All women should have their BMI at booking
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Table 2: Comparison between RBG values at booking and the carbohydrate metabolic status along with the sensitivity, specificity, positive
predictor, and negative predictor values at each RBG range.
RBG value
NGT GDM Sensitivity Specificity Positive predictor Negative predictor[Prevalence]
Chi square
>4.5
149 92 69.2 43.3 38.2 26.5[60.9%]
𝑝 = 0.04
>5.0
70 64 48.1 73.4 47.8 26.3[33.8%]
𝑝 < 0.0001
>5.6
34 52 39.1 87.1 60.5 26.1[21.7%]
𝑝 < 0.0001
>6.0
26 35 26.3 90.1 57.4 29.3[15.4%]
𝑝 < 0.0001
>6.6
8 25 18.8 97.0 75.8 29.8[8.3%]
𝑝 < 0.0001
>7.0
6 16 14.4 97.7 72.7 31.7[5.6%]
𝑝 < 0.0001
Table 3: Comparison between FBG values and the carbohydrate metabolic status along with the sensitivity, specificity, positive predictor, and
negative predictor values at each FBG range.
FBG
NGT GDM Sensitivity Specificity Positive predictor Negative predictor[Prevalence]
Chi square
>4.5
96 80 60.2 63.5 45.5 24.1[44.4%]
𝑝 < 0.0001
>5.0
0 64 48.1 100.0 100.0 20.8[16.2%]
𝑝 < 0.0001
assessed, and any individual with a booking BMI ≥ 30 kg/m2
should be considered high risk and a FBG assessment taken.
The same BMI cutoff point was found to be statistically
significant to prediction for GDM by Crete and Anasti [16].
Those obese women with a FBG ≥ 5.1mmol/L are diagnosed
as suffering from GDM and lifestyle change intervention
and metabolic profiling should be initiated. Hypoglycaemic
medication should be introduced as necessary to maintain
normoglycaemia. Those obese women with a FBG value
of 4.5–5.0mmol/L should have lifestyle change intervention
instituted and should be referred for an oGTT at 24–28 weeks
of gestation. Zhu et al. put a similar screening suggestion
forwardwhere womenwith FBG between 4.4 and 5.1mmol/L
required undergoing an oGTT to confirm or rule out GDM.
In this study, this screening suggestion failed to identify
about 12% of the GDM cases but reduced the number of
oGTTs needed by 50.3% [17]. In aMediterranean population,
a comparative screening protocol failed to identify 10.1% of
the GDM population and required the performance of an
OGTT in 31.1% of the pregnant population [18]. Metabolic
profiling would be introduced with a diagnosis of GDM on
oGTT.
Women with a BMI < 30 kg/m2 should be initially
referred for a RBG at booking. In accordance with the
IADPSG criteria, those with a RBG ≥ 11.1mmol/L would be
immediately considered diabetic [15]. A RBG value of 6.0–
11.0mmol/L should be followed up with a recall for a FBG.
A FBG of ≥5.1mmol/L would be considered diagnostic of
GDM. Such a protocol would ensure a reasonable sensitivity
and specificity, while keeping the proportion of patients
referred for an oGTT to reasonable levels. If the healthcare
facilities allow further testing, it would be reasonable to
consider referring nonobese women with a FBG of 4.5–
5.0mmol/L for an oGTT at 24–28 weeks of gestation. This
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Check BMI at booking
Send for RBG Send for FBG
Consider and manage as GDM
Refer for FBG
Consider as NGT but give lifestyle
and diet advice especially if obese
BMI < 30kg/m2 BMI ≥ 30kg/m2
≥11.1mmol/L ≥5.1mmol/L
69–11.0mmol/L
∗
1
∗
2
Refer for oGTT at 24–28 weeks 4.5–5.0mmol/L
<4.5mmol/L<6.0mmol/L
∗
1: one might also consider recall for FBG
of women with RBG value = 5.5–5.9mmol/L
if healthcare facilities support his load
∗
2: if nonobese FBG value = 4.5–
5.0mmol/L consider referral for
oGTT at 24–28 weeks if healthcare
facilities support this load
Figure 1: GDM screening flowchart based on BMI at booking and RBG/FBG testing.
screening protocol incorporates the new IADPSG diagnostic
criteria that has been accepted and adopted by the World
HealthOrganization (WHO) andAmericanDiabetes Associ-
ation (ADA) [8, 19]. It incorporates the high-risk population
predictor tool as identified in this study. Following such
protocol would help predict GDM at an earlier onset and
reduce the need for cumbersome oGTT test.
The study was performed on data obtained from a conve-
nient sample population rather than a one representative for
the whole pregnant population. This precludes actual calcu-
lation of screening costs with a national health center setting.
There was some lack of data for the prepregnancy BMI
which being dependent on self-reporting of prepregnancy
weight was inherently unreliable and inaccurate. Also there
was no distinction made between any differences in cultural
ethnicity of the pregnant women under study. Furthermore,
the study was performed on a small sample population of
GDMwomen. A larger population sample study is suggested
to evaluate further the proposed screening protocol. Further
studies should be made to assess the outcomes of those
neonates born to unidentified GDMmothers to better assess
the cost-risk ratios.
5. Conclusion
A screening guideline at the first antenatal encounter should
be followed to identify at an early stage those women who are
at risk to develop GDM. A combination of BMI assessment
and RBG and FBG testing appears to be a useful screening
method to identify a good proportion of patients with GDM
without the need for universal screening with an oGTT. All
obese and relative hyperglycaemic patients should receive
lifestyle intervention and dietary advice at the first antenatal
visit. This advice should be reinforced at each subsequent
antenatal visit by keeping a check on the weight gain in
the preceding weeks. Anthropomorphic characteristics along
with RBG and or FBG would predict GDM pregnant women
and reduce the need for oGTT.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
The authors would like to acknowledge all pregnant women
that gave their consent to take part in this study.The research
work disclosed in this publication is partially funded by the
Master it! Scholarship Scheme (Malta). This Scholarship is
part-financed by the European Union-European Social Fund
(ESF) under Operational Programme II-Cohesion Policy
2007–2013, “Empowering People for More Jobs and a Better
Quality of Life.”
6 Scientifica
References
[1] International Diabetes Federation,Diabetes—The Policy Puzzle:
Is Europe Making Progress? IDF, 2011.
[2] International Diabetes Federation, IDF Diabetes Atlas, Interna-
tional Diabetes Federation, Brussels, Belgium, 6th edition, 2013.
[3] World Health Organization, Definition, Diagnosis and Clas-
sification of Diabetes Mellitus and Its Complications, WHO,
Geneva, Switzerland, 1999.
[4] J.M. Lawrence, R. Contreras,W. Chen, andD. A. Sacks, “Trends
in the prevalence of preexisting diabetes and gestational dia-
betes mellitus among a racially/ethnically diverse population of
pregnant women, 1999–2005,” Diabetes Care, vol. 31, no. 5, pp.
899–904, 2008.
[5] C. Savona-Ventura, J. Vassallo, M. Marre, and B. G. Karamanos,
“Hyperglycaemia in pregnancy inMediterranean women,”Acta
Diabetologica, vol. 49, no. 6, pp. 473–480, 2012.
[6] A. Bergho¨fer, T. Pischon, T. Reinhold, C. M. Apovian, A. M.
Sharma, and S.N.Willich, “Obesity prevalence fromaEuropean
perspective: a systematic review,” BMC Public Health, vol. 8,
article 200, 2008.
[7] X. Xiong, L. D. Saunders, F. L. Wang, and N. N. Demianczuk,
“Gestational diabetes mellitus: prevalence, risk factors, mater-
nal and infant outcomes,” International Journal of Gynecology
and Obstetrics, vol. 75, no. 3, pp. 221–228, 2001.
[8] J. Craus, C. Savona-Ventura, and J. Vassallo, “Prevalence of
GDM in the Maltese population,” in Proceedings of the 12th
Meeting of the Mediterranean Group for the Study of Diabetes,
p. 159, MGSD, Gammarth, Tunisia, April-May 2011.
[9] Department of Health Information and Research, European
Health Examination Survery 2010—Pilot Study, Ministry of
Health, The Elderly and Community Care, 2010.
[10] C. Savona Ventura, “The thrifty diet phenotype—a case for
endogenous physiological teratogenesis,” in Birth Defects: New
Research, J. V. Engels, Ed., pp. 183–200, Nova Science, NewYork,
NY, USA, 2006.
[11] S. Fava, J. Azzopardi, A. T. Hattersley, and P. J. Watkins,
“Increased prevalence of proteinuria in diabetic sibs of pro-
teinuric type 2 diabetic subjects,” American Journal of Kidney
Disease, vol. 35, no. 4, pp. 708–712, 2000.
[12] International Diabetes Federation, Diabetes in Europe, Policy
Puzzle—The State We Are in, European Coalition for Diabetes,
4th edition, 2014.
[13] N. I. Jowett, A. K. Samanta, and A. C. Burden, “Screening for
diabetes in pregnancy: is a random blood glucose enough?”
Diabetic Medicine, vol. 4, no. 2, pp. 160–163, 1987.
[14] M. Van Leeuwen, B. C. Opmeer, Y. Yilmaz, J. Limpens, M. J.
Serlie, and B. W. J. Mol, “Accuracy of the random glucose test
as screening test for gestational diabetes mellitus: a systematic
review,” European Journal of Obstetrics Gynecology & Reproduc-
tive Biology, vol. 154, no. 2, pp. 130–135, 2011.
[15] American Diabetes Association, “Standards of medical care in
diabetes—2014,” Diabetes Care, vol. 37, supplement 1, pp. S14–
S80, 2014.
[16] J. E. Crete and J. N. Anasti, “Diagnosis of gestational diabetes
mellitus: can we avoid the glucose challenge test?” Journal of the
American Association of Nurse Practitioners, vol. 25, no. 6, pp.
329–333, 2013.
[17] W.-W. Zhu, X.-P. Du, L. Fan et al., “Fasting plasma glucose at 24-
28 weeks to screen for gestational diabetes mellitus,” Diabetes
Care, vol. 36, no. 7, pp. 2038–2040, 2013.
[18] C. Savona-Ventura, J. Vassallo, M. Marre, and B. G. Karaman-
dos, “Comment on: Zhu et al. Fasting plasma glucose at 24–28
weeks to screen for gestational diabetes mellitus: new evidence
from China. Diabetes care 2013; 36:2038–2040,” Diabetes Care,
vol. 36, no. 9, article e165, 2013.
[19] B. S. Buckley, J. Harreiter, P. Damm et al., “Gestational diabetes
mellitus in Europe: prevalence, current screening practice and
barriers to screening. A review,” Diabetic Medicine, vol. 29, no.
7, pp. 844–854, 2012.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
